

Special Issue

Study on Clinical Treatment of Brain Tumors

Message from the Guest Editor

In recent years, the development of antineoplastic agents has undergone significant changes, especially in the development of molecularly targeted agents. The number of cases in which regulatory approval has been granted based on the primary efficacy endpoint of response rate in phase II trials is increasing. In addition, many pharmaceuticals are being introduced into clinical practice as genomic medicine, and it is expected that more drugs will be developed for tumors based on genetic abnormalities that are less common in the future. However, brain tumors, especially malignant brain tumors such as glioblastoma, are still an area with a poor prognosis and high unmet medical needs, and the development of new treatment methods, including not only pharmaceuticals but also biotechnology products and medical devices, is sought after, and various clinical trials are being conducted. In this area, it is necessary not only to develop treatments, but also to create a consensus on efficacy endpoints for optimal response. This Special Issue presents recent studies on the clinical treatment of brain tumors, working toward turning various brain tumors into prolonged overall survival.

Guest Editor

Dr. Shinya Watanabe

Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba 305-8575, Ibaraki, Japan

Deadline for manuscript submissions

9 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/205822

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)